Sign Out
Ticagrelor is indicated to reduce the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI). For at least the first 12 months following ACS, it is superior to Clopidogrel.
Ticagrelor also reduces the rate of stent thrombosis in patients who have been stented for treatment of ACS.
Continue with Google